Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifapentine + Isoniazid vs Isoniazid for LTBI in Socially Marginalised People
NCT03266991Phase 4Terminated
- Sponsor
- Aarhus University Hospital
- Start
- Oct 2017
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rifapentine in Tuberculosis (TB) (2 arms), sponsored by Aarhus University Hospital. Primary endpoint: Adherence to Treatment at 2 years. Started Oct 2017; status: terminated.
02
Drugs
rifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03266991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03266991.